These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 37942762)

  • 61. Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial.
    Cottereau AS; Versari A; Loft A; Casasnovas O; Bellei M; Ricci R; Bardet S; Castagnoli A; Brice P; Raemaekers J; Deau B; Fortpied C; Raveloarivahy T; Van Zele E; Chartier L; Vander Borght T; Federico M; Hutchings M; Ricardi U; Andre M; Meignan M
    Blood; 2018 Mar; 131(13):1456-1463. PubMed ID: 29437590
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial.
    Schmitz C; Hüttmann A; Müller SP; Hanoun M; Boellaard R; Brinkmann M; Jöckel KH; Dührsen U; Rekowski J
    Eur J Cancer; 2020 Jan; 124():25-36. PubMed ID: 31710995
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Prognostic value of 18F-FDG lesion dissemination features in patients with peripheral T-cell lymphoma (PTCL).
    Xie Y; Teng Y; Jiang C; Ding C; Zhou Z
    Jpn J Radiol; 2023 Jul; 41(7):777-786. PubMed ID: 36752954
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Prognostic Value of Baseline Total Metabolic Tumor Volume Measured on FDG PET in Patients With Richter Syndrome.
    Pontoizeau C; Girard A; Mesbah H; Haumont LA; Devillers A; Tempescul A; Salaün PY; Lamy T; Le Jeune F; Palard-Novello X
    Clin Nucl Med; 2020 Feb; 45(2):118-122. PubMed ID: 31876819
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma: results from the PETAL trial.
    Broecker-Preuss M; Becher-Boveleth N; Müller SP; Hüttmann A; Hanoun C; Grafe H; Richter J; Klapper W; Rekowski J; Bockisch A; Dührsen U
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2611-2621. PubMed ID: 34708297
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Positron Emission Tomography-Based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin Lymphoma.
    Procházka V; Gawande RS; Cayci Z; Froelich JW; Cao Q; Wilke C; Dusenbery K; Weisdorf DJ; Bachanova V
    Biol Blood Marrow Transplant; 2018 Jan; 24(1):64-70. PubMed ID: 28942016
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Baseline Total Metabolic Tumor Volume is Prognostic for Refractoriness to Immunochemotherapy in DLBCL: Results From GOYA.
    Ruiz IC; Martelli M; Sehn LH; Vitolo U; Nielsen TG; Sellam G; Bottos A; Klingbiel D; Kostakoglu L
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e804-e814. PubMed ID: 35595618
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pretreatment levels of serum soluble interleukin-2 receptor are useful in selecting the treatment regimen for newly diagnosed advanced-stage follicular lymphoma with low tumor burden.
    Nozaki K; Sugahara H; Ueda S; Ishikawa J; Karasuno T; Iida M; Kamae T; Moriyama Y; Kawakami M; Kosugi S; Nakagawa M; Azenishi Y; Sakaniwa R; Kitamura T; Shibayama H
    Int J Hematol; 2021 Aug; 114(2):217-221. PubMed ID: 33847924
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Prognostic value of
    Geng H; Lian K; Zhang W
    Quant Imaging Med Surg; 2024 Jan; 14(1):325-334. PubMed ID: 38223089
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Baseline [
    Marchal E; Palard-Novello X; Lhomme F; Meyer ME; Manson G; Devillers A; Marolleau JP; Houot R; Girard A
    Eur J Nucl Med Mol Imaging; 2024 Jan; 51(2):481-489. PubMed ID: 37721580
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Baseline total lesion glycolysis combined with interim positron emission tomography-computed tomography is a robust predictor of outcome in patients with peripheral T-cell lymphoma.
    Kitadate A; Narita K; Fukumoto K; Terao T; Tsushima T; Kobayashi H; Abe Y; Miura D; Takeuchi M; Machida Y; Matsue K
    Cancer Med; 2020 Aug; 9(15):5509-5518. PubMed ID: 32558387
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Deep learning-based tumour segmentation and total metabolic tumour volume prediction in the prognosis of diffuse large B-cell lymphoma patients in 3D FDG-PET images.
    Jiang C; Chen K; Teng Y; Ding C; Zhou Z; Gao Y; Wu J; He J; He K; Zhang J
    Eur Radiol; 2022 Jul; 32(7):4801-4812. PubMed ID: 35166895
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Clinical application of [
    Díaz-Silván A; Otón-Sánchez LF; Caresia-Aróztegui AP; Del Puig Cózar-Santiago M; Orcajo-Rincón J; de Arcocha-Torres M; Delgado-Bolton RC; Cabello-García D;
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2022; 41(3):202-212. PubMed ID: 35490105
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Whole-Body Diffusion-weighted MR Imaging of Iron Deposits in Hodgkin, Follicular, and Diffuse Large B-Cell Lymphoma.
    Cottereau AS; Mulé S; Lin C; Belhadj K; Vignaud A; Copie-Bergman C; Boyez A; Zerbib P; Tacher V; Scherman E; Haioun C; Luciani A; Itti E; Rahmouni A
    Radiology; 2018 Feb; 286(2):560-567. PubMed ID: 28985135
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study.
    Cottereau AS; Versari A; Luminari S; Dupuis J; Chartier L; Casasnovas RO; Berriolo-Riedinger A; Menga M; Haioun C; Tilly H; Tarantino V; Federico M; Salles G; Trotman J; Meignan M
    Blood; 2018 May; 131(22):2449-2453. PubMed ID: 29559480
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Prognostic Impact of Pretreatment 2-[
    Albano D; Dondi F; Mazzoletti A; Bellini P; Giubbini R; Bertagna F
    Medicina (Kaunas); 2021 May; 57(5):. PubMed ID: 34069203
    [No Abstract]   [Full Text] [Related]  

  • 78.
    Mi L; Zhao Y; Zhao X; Yin F; Yin X; Li N; Shi J; Han X; Duan X; Zhao M; Han G; Wang J
    Cancer Biother Radiopharm; 2021 Oct; 36(8):662-671. PubMed ID: 32783634
    [No Abstract]   [Full Text] [Related]  

  • 79.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET/CT as independent prognostic biomarkers of recurrence in resected breast cancer.
    Seban RD; Rouzier R; Latouche A; Deleval N; Guinebretiere JM; Buvat I; Bidard FC; Champion L
    Eur J Nucl Med Mol Imaging; 2021 Oct; 48(11):3560-3570. PubMed ID: 33774685
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.